Reprogrammed Interchange Llc Sells 284,805 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold a total of 284,805 shares of Vor Biopharma at an average price of $1.83, resulting in proceeds of approximately $521,193.15, and now holds 33,928,487 shares valued at about $62 million.
• Vor Biopharma's stock price has dropped 8.0% recently, trading at $1.60, amid significant trading volume of 6,009,423 shares.
• Several institutional investors have recently increased their stakes in Vor Biopharma, with 97.29% of the stock now held by hedge funds and other institutions.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 284,805 shares of the company's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $1.83, for a total value of $521,193.15. Following the completion of the transaction, the insider directly owned 33,928,487 shares of the company's stock, valued at approximately $62,089,131.21. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, September 15th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.64, for a total value of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 300,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.75, for a total value of $525,000.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 464,421 shares of Vor Biopharma stock. The stock was sold at an average price of $1.99, for a total value of $924,197.79.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.82, for a total value of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total value of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.97, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total value of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total value of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total value of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total value of $1,229,410.47.

Vor Biopharma Stock Down 8.0%

Vor Biopharma stock traded down $0.14 during midday trading on Monday, reaching $1.60. 6,009,423 shares of the stock traded hands, compared to its average volume of 7,617,477. The stock's fifty day moving average is $2.12 and its 200-day moving average is $1.13. Vor Biopharma Inc. has a 12 month low of $0.13 and a 12 month high of $3.29. The stock has a market cap of $202.69 million, a P/E ratio of -0.97 and a beta of 2.05.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. OMERS ADMINISTRATION Corp bought a new position in Vor Biopharma in the first quarter worth approximately $100,000. Northern Trust Corp grew its stake in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. Money Concepts Capital Corp grew its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new position in Vor Biopharma in the fourth quarter worth approximately $102,000. Finally, Jane Street Group LLC bought a new position in Vor Biopharma in the first quarter worth approximately $140,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of Vor Biopharma in a research report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, Vor Biopharma has an average rating of "Moderate Buy" and a consensus price target of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.